Goldman Sachs
May 13, 2026
Olympus Earnings Review Results and Guidance Beat Expectations
Single Stock ReportEquitiesHealth Care
Olympus reported FY3/26 results and FY3/27 guidance that both exceeded expectations, driven by strong Gastrointestinal Solutions sales in Western markets. Goldman Sachs maintains its Buy rating and raised the target price to ¥2,050.
Key Takeaways
- 1.Olympus FY3/26 adjusted operating profit of ¥143.3 bn beat Goldman Sachs estimates of ¥134.5 bn due to favorable sales in the Gastrointestinal Solutions (GIS) business.
- 2.FY3/27 guidance for adjusted operating profit is ¥160.5-179.5 bn, which is higher than the previously estimated ¥154.6 bn.
- 3.The company announced a share buyback program of up to ¥60.0 bn (4.18% of shares) starting May 13, 2026.
Table of Contents
- Results overview and GSe revisions
- Key Data
- GS Forecast
- GS Factor Profile
- Ratios & Valuation
- Growth & Margins (%)
- Price Performance
- Income Statement (¥ bn)
- Balance Sheet (¥ bn)
- Cash Flow (¥ bn)
- Price Target Risks and Methodology - Olympus
- Investment Thesis - Olympus
- Disclosure Appendix
Document Preview
Access the Full Report
Get unlimited access to institutional research reports with a 14-day free trial.
Authors
Akinori Ueda, Ph.D.Tomo Taniguchi
Securities
Olympus
Themes
Medtech Earnings RecoveryRegulatory Compliance and Quality Management
Regions
Asia PacificEuropeJapanUnited StatesChina